Site search

Clear filter
2897 results for '' found
A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants with NHL and CLL (NCT05424822)
A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants with NHL and CLL (NCT05424822)
/
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of
/
Australian Centre of Excellence in Melanoma Imaging & Diagnosis (ACEMID) Cohort Study (ACTRN12619001706167)
/
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psor
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psor
/
2-fraction Stereotactic ultra-HypOfractionated radiation Therapy of the proState (ACTRN12625000198426)
2-fraction Stereotactic ultra-HypOfractionated radiation Therapy of the proState (ACTRN12625000198426)
/
First-in-Human, Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of a Single-Induction Dose of convertibleCAR™-T Cells Armed with MicAbody™ Protein
First-in-Human, Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of a Single-Induction Dose of convertibleCAR™-T Cells Armed with MicAbody™ Protein
/
A Phase 1b Open-label Study to Investigate the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults with Relapsed or Refractory B cell Precursor
A Phase 1b Open-label Study to Investigate the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults with Relapsed or Refractory B cell Precursor
/
Interventional, randomized, double-blind, parallel-group, placebo-controlled study of add-on eptinezumab treatment to brief educational intervention for the preventive treatment of migraine in pa
/
A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (NCT05936359)
A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (NCT05936359)
/
Comparing speech pathology and amitriptyline to speech pathology and placebo for the management of vocal cord dysfunction: a randomised controlled trial (ACTRN12619000158167)
Comparing speech pathology and amitriptyline to speech pathology and placebo for the management of vocal cord dysfunction: a randomised controlled trial (ACTRN12619000158167)
/
69 70 71 72 73